BFAM Partners’s Takeda Pharmaceutical TAK Stock Holding History

BFAM Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-328,690	Closed	-$6M	–	16
2021 Q1	$6M	Buy	+328,690	New	+$5.91M	2.36%	6

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFAM Partners's TAK Position: Q2 2021 in Review

BFAM Partners sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 328,690 shares — an estimated $6M sold.

BFAM Partners first reported a position in TAK in Q1 2021 and held it in 1 quarter. The position peaked at $6M in Q1 2021. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

BFAM Partners reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
BFAM Partners sold 328,690 Takeda Pharmaceutical shares in Q2 2021, an estimated $6M.
BFAM Partners first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 1 quarter.
BFAM Partners's Takeda Pharmaceutical position peaked at $6M in Q1 2021.
304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on BFAM Partners's 13F filing for Q2 2021, filed 11 Aug 2021.